

Syngene

Putting Science to Work

Discovery Biology & Biotherapeutics



Science
For People
**ADVANCING
INNOVATION**

Integrated Expertise
from Target Biology to
Therapeutic Candidate





Partner with Syngene - Where Innovation Meets Excellence

With over 32 years of experience, Syngene is a trusted global CRDMO, delivering end-to-end solutions across discovery, development, and manufacturing. Our integrated platform positions us as a true 'one-stop-shop' for solving complex scientific challenges. Over 400 customers globally rely on our scientific excellence, reflected in more than 400 client-assigned patents recognizing our contributions to their breakthroughs




Having a single partner with a broad suite of capabilities as opposed to multiple specialty partners, means being able to manage projects centrally, unhindered by logistical / shipping delays or dependencies on third-party deliverables. This enables timely completion of projects, efficiency, and cost savings.


Syngene offers end-to-end Biologics Development and Manufacturing solutions for mammalian and microbial systems across modalities and therapeutic areas. We also offer Sterile Fill-Finish and Viral Testing services, making us a one-stop solution for all Biologics requirements - Target to Therapy!




Antibody Discovery: Leveraging Multiple Platforms for Biotherapeutic and Tool Antibodies




We Can Generate Antibodies in ~12 Weeks Using RIMMS Approach and ~ 21 Weeks Using Standard Immunization Approach



We Offer a Rich Suite of Antibody Engineering Capabilities




Capabilities to Support Your End-to-end ADC Research and Development



GMP manufacturing of antibody, linker, payload, and conjugation.

Unlock Breakthroughs with Syngene's Genomic and Translational Sciences



Syngene offers a comprehensive suite of services across cloning, next-generation sequencing (NGS), mRNA synthesis, antibody repertoire sequencing, therapeutic antibody discovery, and biomarker identification.


Our expertise spans fast-turnaround gene cloning, custom vector design, full-spectrum NGS, high-quality mRNA production with LNP formulation, and advanced immune repertoire analysis. Leveraging cutting-edge phage and yeast display platforms, we rapidly discover and optimize therapeutic and diagnostic antibodies against a wide range of targets.

Our biomarker discovery capabilities further empower precision medicine initiatives by delivering clinically actionable insights.

Partner with Syngene to translate genomic data into meaningful breakthroughs.



NGS & Sanger Sequencing Services




Cell Engineering - One Stop Solution for Reagent Cell Line Generation

TATs (in weeks)	8-12	Over Expression Cells (Pools and Monoclones)	Low, med & high expressors
	10-12	Knock Out Cells	Pools and monoclones
	12-14	Knock In Cell Lines	HiBiT, eGFP single base pair/aa substitution
	1-2	Receptor Density Analysis	HiBiT, eGFP and antibodies
	8-12	Reporter Cell Lines	Cell signalling Luciferase, eGFP
	4-5	Viral Production and Packaging	Lenti, retro, AAV
	6-10	Landing Pad Technology	Pool equivalent to monoclonal
	1-2	Transfection Studies	Electroporation with ~ 80% efficiency

- Syngene cell engineering team offers one stop solution for all reagent cell lines which can be used for various aspects of pharmacological and small molecule drug discovery
- Our expertise having very ~ 22 years of experience in cell line engineering equipped us to provide quicker and scientific and strategic solutions to generate knock out in any given cell line. We successfully tested our optimised protocol in ~ 80 cell lines
- Our expertise in over expression lines enables us to generate cells with differential receptor densities which serves as excellent tools for ADC and CDCC assays
- Lentiviral based design of reporter vectors lead us to generate reporter cell lines for various signaling pathways with high sensitivity as low as nM range detection with longer stability up to ~ 20 passages
- We are well equipped with designing new vectors according to the client needs from the scratch. This enables stable expression of target genes over ~ 20 passages or 40 generations
- Our landing pad technology developed at safe harbour site provides us to generate monoclonal cell lines as quick as us to generate monoclones equivalent cell lines as quick as ~ 6 weeks
- In addition, we offer transient transfection studies, siRNA, shRNA and viral vector designing and generation



Work Flow for Knock Out and Knock in Generations and QC



Accelerate Your Biologics Development & Bio Manufacturing With Our Expertise



Cell Line Development

- Proprietary CHO line
- Transposon transfection
- 9 weeks DNA to RCB
- > 95% clonal stability



Analytics

- Product characterization
- Bioassays
- Mass Spec, NMR, AUC
- Release & stability assays




Process Development

- High throughput
- USP | DSP
- Process optimization
- Process characterization



Clinical Batch Manufacturing

- 50 L - 4 KL SUBs
- 50 KL global SUB capacity
- Formulation | F&F
- Viral clearance



Our Competence - Your Advantage



Trust

- 25+ INDs enabled
- Top 15 global biopharma clients
- 140+ successful projects



Speed & Reliability

- 10 months from CLD to clinic
- Real time data sharing
- Start within 4 weeks from signing



Success by Design

- 7-12 g/L titers achieved
- Proven process scalability
- End-to-end in-house service




Value


- Uncompromised quality
- Royalty-free
- Flexible payment structure

Drug Substance and Drug Product Manufacturing Services

- Dual manufacturing site in India and in the U.S. ensuring seamless supply continuity
- Total single use bioreactor (SUB) capacity of 50,000 liters, with individual SUBs ranging from 50 to 4000 liters
- Our India manufacturing site is approved by USFDA, EMA, ANVISA, and PMDA and has produced more than 250 GMP batches
- Drug product services: Vials | PFS | Cartridges
- Integrated capacity of 1 million vials per day



Sequence to Vial in 10 Months



About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated CRDMO (Contract Research, Development and Manufacturing Organization), serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's ~6000 scientists bring the skills and capacity to deliver great science, strong data security, and quality manufacturing, at speed, helping improve time-to-market and lower the cost of innovation. This is backed by ring-fenced dedicated centers, as well as ~3 Mn sq. ft of specialist discovery, development, and manufacturing facilities.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com